X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs VENUS REMEDIES - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE VENUS REMEDIES CADILA HEALTHCARE/
VENUS REMEDIES
 
P/E (TTM) x 24.1 -9.0 - View Chart
P/BV x 6.0 0.1 4,317.0% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 CADILA HEALTHCARE   VENUS REMEDIES
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-17
VENUS REMEDIES
Mar-17
CADILA HEALTHCARE/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs460143 322.1%   
Low Rs30565 469.2%   
Sales per share (Unadj.) Rs92.1324.2 28.4%  
Earnings per share (Unadj.) Rs14.86.4 231.1%  
Cash flow per share (Unadj.) Rs18.540.6 45.5%  
Dividends per share (Unadj.) Rs3.200-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs68.0366.0 18.6%  
Shares outstanding (eoy) m1,023.7412.34 8,296.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.20.3 1,295.7%   
Avg P/E ratio x25.816.2 159.3%  
P/CF ratio (eoy) x20.72.6 808.3%  
Price / Book Value ratio x5.60.3 1,981.7%  
Dividend payout %21.60-   
Avg Mkt Cap Rs m391,5811,282 30,541.5%   
No. of employees `00016.90.9 1,866.6%   
Total wages/salary Rs m15,002251 5,976.9%   
Avg. sales/employee Rs Th5,594.54,430.1 126.3%   
Avg. wages/employee Rs Th890.1278.0 320.2%   
Avg. net profit/employee Rs Th899.987.6 1,027.3%   
INCOME DATA
Net Sales Rs m94,2954,000 2,357.1%  
Other income Rs m1,28623 5,665.2%   
Total revenues Rs m95,5814,023 2,375.8%   
Gross profit Rs m19,036785 2,425.9%  
Depreciation Rs m3,750422 889.5%   
Interest Rs m450344 130.9%   
Profit before tax Rs m16,12242 38,294.5%   
Minority Interest Rs m3380-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-30-   
Tax Rs m1,289-37 -3,483.8%   
Profit after tax Rs m15,16879 19,175.7%  
Gross profit margin %20.219.6 102.9%  
Effective tax rate %8.0-87.9 -9.1%   
Net profit margin %16.12.0 813.5%  
BALANCE SHEET DATA
Current assets Rs m60,2232,606 2,310.8%   
Current liabilities Rs m53,0581,980 2,679.3%   
Net working cap to sales %7.615.6 48.6%  
Current ratio x1.11.3 86.2%  
Inventory Days Days70128 54.4%  
Debtors Days Days8843 204.3%  
Net fixed assets Rs m72,9845,353 1,363.4%   
Share capital Rs m1,024123 829.8%   
"Free" reserves Rs m68,5764,393 1,561.2%   
Net worth Rs m69,6004,516 1,541.2%   
Long term debt Rs m24,6841,618 1,525.4%   
Total assets Rs m152,2078,291 1,835.8%  
Interest coverage x36.81.1 3,280.8%   
Debt to equity ratio x0.40.4 99.0%  
Sales to assets ratio x0.60.5 128.4%   
Return on assets %10.35.1 201.2%  
Return on equity %21.81.8 1,244.2%  
Return on capital %17.96.3 285.1%  
Exports to sales %00-   
Imports to sales %018.4 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA736 0.0%   
Fx inflow Rs m21,2800-   
Fx outflow Rs m10,874736 1,476.8%   
Net fx Rs m10,406-736 -1,413.3%   
CASH FLOW
From Operations Rs m13,495997 1,353.3%  
From Investments Rs m-29,103-461 6,308.9%  
From Financial Activity Rs m23,158-571 -4,055.7%  
Net Cashflow Rs m7,556-35 -21,527.1%  

Share Holding

Indian Promoters % 74.8 32.9 227.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 0.2 4,611.1%  
FIIs % 5.9 0.6 1,017.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 66.4 16.6%  
Shareholders   44,069 20,121 219.0%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   FULFORD INDIA  AUROBINDO PHARMA  IPCA LABS  WOCKHARDT LTD.  SUN PHARMA  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Volatile Day in Red; Pharma Stocks Lose Most(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2%

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY18); Net Profit Up 50.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, CADILA HEALTHCARE has posted a net profit of Rs 6 bn (up 50.4% YoY). Sales on the other hand came in at Rs 33 bn (up 28.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Jun 21, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - STRIDES SHASUN LTD COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS